AzTrials
AzTrials

Fall Risk, Fall PreventionHD Fall RiskNCT07380191

EFFECT OF PLAZEPOD VERSUS ELECTRICAL STIMULATION ON RISK OF FALLING IN HEMODIALYSIS PATIENTS

A study testing Device + Behavioral and Neuromuscular Electrical Stimulation (NMES) in people with Fall Risk, Fall Prevention, run by Cairo University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Renal nutrition Fluid control Safe physical activity Sleep hygiene, energy and managing fatigue Adherence and awareness Read more about this study

Who is it for?
Ages 40 to 50 years, men only
Conditions the study is for
Fall Risk, Fall Prevention
What is being tested?
Device + Behavioral and Neuromuscular Electrical Stimulation (NMES)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteEgypt
Study dates
21 Mar 2026to 22 Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 50 years
  • Men only
  • No healthy volunteers
  • Adult

Who may be able to join

  • :
  • Male patients aged 40 to 50 years.
  • Diagnosed with end-stage renal disease and receiving maintenance hemodialysis for at least 6 months.
  • Medically stable and cleared by a nephrologist to participate in physical activity and/or electrical stimulation.
  • Able to ambulate independently or with minimal assistance.
  • Cognitively able to understand study procedures.
  • Not participating in any other structured exercise program.

Who cannot join

  • Severe neurological or orthopedic disorders affecting mobility.
  • Unstable cardiovascular conditions.
  • Cognitive impairment or sensory deficits.
  • Contraindications to neuromuscular electrical stimulation.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Samia Wagdy El said Diab, PHD contact

01094762028 ext. 01094762028

Samiaahmeddiab@gmail.com

Egypt1 site
  • Tanta

    Tanta, Alquarbia, 31111

    Sally Hafez Mohamed el said, Phd, 0100101111315 ext. 0100101111315, ysaly094@gmail.com

    Heba Ali ABDELGHAFAR ALI, Phd

Other trials in Egypt

About this study

Renal nutrition Fluid control Safe physical activity Sleep hygiene, energy and managing fatigue Adherence and awareness

Read the detailed description

Application of PlazePod Device and Electrical Stimulation and comparison between them to decrease fall Risk in Hemodialysis Patients

Being tested
Device + Behavioral, Neuromuscular Electrical Stimulation (NMES)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Device + BehavioralDevice

    This intervention consists of interactive sensorimotor training using the BlazePod system, a visual stimulus-based device designed to improve balance, coordination, reaction time, and functional mobility. Participants will perform static and dynamic balance exercises, reactive stepping drills, lower-limb coordination tasks, and dual-task activities in response to visual cues emitted by the BlazePod sensors. Training sessions will be conducted three times per week, with each session lasting 30 minutes, over a total duration of 12 weeks. All sessions will be supervised by a licensed physical therapist to ensure safety and appropriate progression of exercise difficulty. The intervention aims to reduce fall risk by enhancing neuromuscular control and postural stability in hemodialysis patients.

  • Neuromuscular Electrical Stimulation (NMES)Device

    This intervention involves the application of neuromuscular electrical stimulation to the lower limb muscles, specifically the bilateral quadriceps and hamstrings, using a portable electrical stimulation device. Surface electrodes will be placed over the motor points to elicit visible and comfortable muscle contractions. Stimulation parameters will include a frequency of 35-50 Hz, pulse width of 200-400 microseconds, and a duty cycle of 10 seconds on and 30 seconds off. Sessions will be administered three times per week for 30 minutes over 12 weeks under the supervision of a physical therapist. The intervention aims to improve muscle strength, balance, functional mobility, and reduce fall risk in hemodialysis patients.

Study groups in NCT07380191
Study groupRoleWhat they receive
BlazePod Training plus Lifestyle EducationExperimentalParticipants in this arm will receive an interactive sensorimotor training program using the BlazePod system combined with a structured lifestyle education program. BlazePod training will focus on improving balance, reaction time, coordination, and functional mobility through static and dynamic balance tasks, reactive stepping, and lower-limb coordination exercises. Training sessions will be conducted three times per week for 30 minutes over a period of 12 weeks under the supervision of a physical therapist. In addition, participants will attend a weekly lifestyle education session addressing renal nutrition, fluid management, safe physical activity, fall prevention strategies, sleep hygiene, fatigue management, and medication adherence.
Receives: Device: Neuromuscular Electrical Stimulation (NMES)
Tens plus Lifestyle EducationActive comparatorParticipants in this arm will receive neuromuscular electrical stimulation (NMES) applied to the lower limb muscles, including bilateral quadriceps and hamstrings, combined with the same structured lifestyle education program as the experimental group. NMES will be delivered using a portable electrical stimulation device with parameters adjusted to produce visible and comfortable muscle contractions. Sessions will be conducted three times per week for 30 minutes over 12 weeks under physical therapist supervision. Lifestyle education sessions will be provided once weekly and will include renal nutrition, fluid control, safe physical activity, fall prevention strategies, sleep hygiene, fatigue management, and medication adherence.
Receives: Device: Device + Behavioral; Device: Neuromuscular Electrical Stimulation (NMES)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Risk of Falling Assessed by Timed Up and Go Test (TUG)

    Change in risk of falling measured using the Timed Up and Go (TUG) test, recorded in seconds. Lower scores indicate better functional mobility and reduced fall risk.

    Measured: Baseline and after 12 weeks of intervention

  2. Balance Performance Assessed by Berg Balance Scale (BBS)

    Change in static and dynamic balance measured using the Berg Balance Scale (BBS), scored from 0 to 56 points, with higher scores indicating better balance performance.

    Measured: Baseline and after 12 weeks

  3. Lower Limb Muscle Strength

    Change in lower limb muscle strength measured using a hand-held dynamometer, recorded in kilograms (kg).

    Measured: Baseline and after 12 weeks

Secondary outcomes (2)
  1. Physical Activity Level

    Change in physical activity level measured using the International Physical Activity Questionnaire - Short Form (IPAQ-SF), expressed in MET-minutes/week.

    Measured: Baseline and after 12 weeks

  2. Kidney Disease-Related Quality of Life

    Change in quality of life measured using the Kidney Disease Quality of Life Short Form questionnaire (KDQOL-36), reported as total score.

    Measured: Baseline and after 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Feb 2026
  2. Study start21 Mar 2026 (estimated)
  3. Primary completion22 Dec 2026 (estimated)
  4. Study completion22 Mar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Application two Devices of PlazePod Device and Electrical Stimulation for 60 patients each group 30 for 3months for 40-50age Additionally life style education program, such as: Renal nutrition Fluid control Safe physical activity Sleep hygiene, energy and managing fatigue Adherence and awareness For 3 months, there was one session every week, lasting 30 minutes and comparison between two groups
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07380191
Sponsor's protocol ID
CairoU physical therapy
Acronym
HD Fall Risk
Status last verified
Jan 2026
First submitted
15 Jan 2026
Last updated
2 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: "At this time, we have not decided whether individual participant data will be shared. This is due to considerations of patient privacy, confidentiality, and ongoing analysis. A decision regarding data sharing will be made after study completion and in accordance with ethical guidelines."

Questions about this trial

What is this clinical trial studying?

A study testing Device + Behavioral and Neuromuscular Electrical Stimulation (NMES) in people with Fall Risk, Fall Prevention, run by Cairo University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 2 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Samia Wagdy El said Diab, PHD (01094762028 ext. 01094762028, Samiaahmeddiab@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Risk of Falling Assessed by Timed Up and Go Test (TUG) (time frame: Baseline and after 12 weeks of intervention). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in